Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression

Axsome Therapeutics, Inc. (NASDAQ:AXSM) enrolled the first patient in the STRIDE-1 (Symptom Treatment in Resistant Depression 1) study, a Phase 3 trial evaluating the efficacy and safety of AXS-05 for the treatment of treatment resistant depression (TRD). AXS-05 is an innovative oral therapeutic, with activity at several key neurotransmitter systems, being developed for the treatment of CNS disorders. AXS-05 combines mechanisms of action of several distinct antidepressant drug classes.
Randall Kaye, M.D., Chief Medical Officer of Axsome commented:

We believe that AXS-05 holds promise in this indication due its multiple mechanisms of action, which result in a unique pharmacological profile that may have broad therapeutic applicability. We look forward to learning more about AXS-05 and its potential for treatment resistant depression through the STRIDE-1 study.

Herriot Tabuteau, M.D., Chief Executive Officer of Axsome stated:

The launch of STRIDE-1 is a significant milestone for Axsome. Axsome has now advanced two product candidates into pivotal trials. We remain committed to developing novel therapeutics for unmet medical needs.

Click here to view the full press release.